Mycograb

RSS

Refused

This medicine has been refused authorisation

efungumab
MedicineHumanRefused

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 16 November 2006, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mycograb 2 mg/ml powder for solution for injection intended for the treatment of invasive candidiasis in adult patients, in combination with amphotericin B or a lipid formulation of amphotericin B.

The company that applied for authorisation is NeuTec Pharma plc. The applicant requested a reexamination of the opinion.

After having considered the grounds for this request, the CHMP reexamined the initial opinion, and confirmed the refusal of the marketing authorisation on 20 March 2007.

български (BG) (140.06 KB - PDF)

Rodyti

español (ES) (34.92 KB - PDF)

Rodyti

čeština (CS) (122.04 KB - PDF)

Rodyti

dansk (DA) (34.56 KB - PDF)

Rodyti

Deutsch (DE) (35.59 KB - PDF)

Rodyti

eesti (ET) (34.34 KB - PDF)

Rodyti

ελληνικά (EL) (131.67 KB - PDF)

Rodyti

français (FR) (35.38 KB - PDF)

Rodyti

italiano (IT) (35.17 KB - PDF)

Rodyti

latviešu (LV) (123.74 KB - PDF)

Rodyti

lietuvių (LT) (118.82 KB - PDF)

Rodyti

magyar (HU) (115.52 KB - PDF)

Rodyti

Malti (MT) (126.82 KB - PDF)

Rodyti

Nederlands (NL) (35.55 KB - PDF)

Rodyti

polski (PL) (123.88 KB - PDF)

Rodyti

português (PT) (35.01 KB - PDF)

Rodyti

română (RO) (118.6 KB - PDF)

Rodyti

slovenčina (SK) (120 KB - PDF)

Rodyti

slovenščina (SL) (113.73 KB - PDF)

Rodyti

suomi (FI) (34.59 KB - PDF)

Rodyti

svenska (SV) (34.96 KB - PDF)

Rodyti

Product details

Name of medicine
Mycograb
Active substance
recombinant human monoclonal antibody to hsp
International non-proprietary name (INN) or common name
efungumab
Therapeutic area (MeSH)
Candidiasis
Anatomical therapeutic chemical (ATC) code
J02

Pharmacotherapeutic group

Antimycotics for systemic use

Application details

EMA product number
EMEA/H/C/000658
Marketing authorisation applicant
NeuTec Pharma plc
Opinion adopted
20/03/2007
Refusal of marketing authorisation
22/05/2007

Assessment history

This page was last updated on

Share this page